Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AXIM BIOTECHNOLOGIES, INC.AXIM · Entity 9689 | Director | March 15, 2024 | March 19, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AXIM BIOTECHNOLOGIES, INC.
Report date March 15, 2024 · Filed March 19, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Convertible NoteSEC Table II · derivative / convertible security · Conversion / exercise price $0.01 · Expires 2034-03-01 | Direct | 4,500,000 |
Reported balance
After 2024-03-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-03-15 · Grant · Acquired 35,000 · Balance 4,500,000 F1: Reporting Person acquired a Convertible Note, face value $35,000. The Note is convertible into shares of the Issuer's common stock at a price of $0.01 per share. |
Filing footnotes · ownership attribution and instrument terms
F1: Reporting Person acquired a Convertible Note, face value $35,000. The Note is convertible into shares of the Issuer's common stock at a price of $0.01 per share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 15, 2024 Filed Mar 19, 2024 19:33 UTC | AXIM BIOTECHNOLOGIES, INC. AXIM · Entity 9689 | GrantConvertible Note · Derivative | 35,000 | $35,000.00 Strike: $0.01 | $1,225,000,000.00 |
DisclosureSEC source: 0001096906-24-000520 · form4.xml · derivative · entry 1 Cunningham Robert L · CIK 0001708731 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,500,000 Underlying: Common Stock · 3,500,000 shares Expires 2034-03-01 F1 · shares: Reporting Person acquired a Convertible Note, face value $35,000. The Note is convertible into shares of the Issuer's common stock at a price of $0.01 per share. Read SEC document |
| September 23, 2022 Filed Sep 23, 2022 16:29 UTC | AXIM BIOTECHNOLOGIES, INC. AXIM · Entity 9689 | GrantOption · Derivative | 1,000,000 | $0.00 Strike: $0.05 | $0.00 |
DisclosureSEC source: 0001096906-22-002335 · form4.xml · derivative · entry 1 Cunningham Robert L · CIK 0001708731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500,000 Underlying: Common Stock · 1,000,000 shares Expires 2032-08-22 F1 · derivative.exercise_date: Reporting Person acquired an option to purchase up to 1,000,000 shares of common stock. 50% of the shares may be purchased immediately and the remaining 50% of the shares may purchased at the date which is six (6) months following the grant date. Read SEC document |
| May 13, 2020 Filed Sep 23, 2022 16:27 UTC | AXIM BIOTECHNOLOGIES, INC. AXIM · Entity 9689 | GrantOption · Derivative | 500,000 | $0.00 Strike: $0.01 | $0.00 |
DisclosureSEC source: 0001096906-22-002334 · form4.xml · derivative · entry 1 Cunningham Robert L · CIK 0001708731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2030-03-13 F1 · derivative.exercise_date: Reporting Person acquired the option to purchase 500,000 shares of Issuer's common stock ("Option Shares") on May 13, 2020 (the "Date of Grant"). One-third of the Option Shares will vest on the Date of Grant; (iii) one-third of the Option Shares will vest six (6) months from the Date of Grant; and (iv) the remaining one-third of the Option Shares shall vest twelve (12) Months from the Date of Grant, provided, however, that there has not been a Termination of Service as of such date. In no event shall the Option become exercisable for any additional Option Shares after a Termination of Service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.